Haematologica (May 2024)

Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets

  • Pierre Stephan,
  • Jimmy Perrot,
  • Allison Voisin,
  • Maud Barbery,
  • Thibault Andrieu,
  • Maxime Grimont,
  • Julie Caramel,
  • Mathilde Bardou,
  • Garance Tondeur,
  • Edoardo Missiaglia,
  • Philippe Gaulard,
  • François Lemmonier,
  • Laurence de Leval,
  • Emmanuel Bachy,
  • Pierre Sujobert,
  • Laurent Genestier,
  • Alexandra Traverse-Glehen,
  • Yenkel Grinberg-Bleyer

DOI
https://doi.org/10.3324/haematol.2023.284448
Journal volume & issue
Vol. 999, no. 1

Abstract

Read online

Whereas immunotherapies have revolutionized the treatment of different solid and hematological cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCLs) is limited, due to a lack of understanding of the immune response they trigger. To fully characterize the immune tumor microenvironment (TME) of PTCLs, we performed spectral flow cytometry analyses on 11 angioimmunoblastic T-cell lymphomas (AITL), 7 PTCL, not otherwise specified (PTCL, NOS) lymph node samples, and 10 non-tumoral control samples. The PTCL TME contained a larger proportion of regulatory T cells and exhausted CD8+ T cells, with enriched expression of druggable immune checkpoints. Interestingly, CD39 expression was up-regulated at the surface of most immune cells, and a multi-immunofluorescence analyses on a retrospective cohort of 43 AITL patients demonstrated a significant association between high CD39 expression by T cells and poor patient prognosis. Together, our study unravels the complex TME of nodal PTCLs, identifies targetable immune checkpoints, and highlights CD39 as a novel prognostic factor.